Vimarsana
Biggest News Aggregation in the World

Cabo Atezo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cabo Atezo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cabo Atezo Today - Breaking & Trending Today

Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript - Vimarsana News

Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript

Published: May 2, 2024

Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript April 30, 2024 Exelixis, Inc. misses on earnings expectations. Reported EPS is $0.17 EPS, expectations were $0.28. EXEL isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, ladies and gentlemen, and […]

Source: yahoo.com
Related Topics:
Michael MorrisseyPeter LambJennifer ChanCabo AtezoMonty PalLaura DillardNeeraj AgarwalJoe CatanzaroDana AftabBroad InstituteAlliance For Clinical Trials In OncologyClinical TrialsScientific StrategyHuman ResourcesAmy PetersonMike Morrissey
Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript - Vimarsana News

Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript

Published: May 2, 2024

Exelixis, Inc. misses on earnings expectations. Reported EPS is $0.17 EPS, expectations were $0.28.

Source: insidermonkey.com
Related Topics:
United StatesVarant ShirvanianMichael SchmidtAmy PetersonMike MorrisseyPeter LambChris SennerNeeraj AgarwalChristopher SennerDana AftabMichael MorrisseyMonty PalJennifer ChanJoe CatanzaroJason GerberryLaura DillardCabo AtezoJoseph CatanzaroBroad InstituteAlliance For Clinical Trials In OncologyExelixis IncFastest Growing Fintech CompaniesExchange CommissionCall Transcript AprilExelixis First Quarter
Relapsed/Refractory Clear Cell RCC: Novel Treatment Strategies - Vimarsana News

Relapsed/Refractory Clear Cell RCC: Novel Treatment Strategies

Published: July 17, 2023

Switching their focus to relapsed/refractory advanced clear cell renal cell carcinoma, key opinion leaders review treatment options in this setting.

Source: onclive.com
Related Topics:
Evolving TreatmentsAdvanced Renal Cell CarcinomaNovel TreatmentRenal Cell CarcinomaRcc CancerKidney CancerAdvanced RccMetastatic RccAsco 2023Asco Annual MeetingContact 03Ipi NivoNivo IpiCabo AtezoAtezo CaboTinivo 2Cabo NivoCombination TherapyNovel TherapySequencing Therapy